Molecular biology of leukemia

Current Oncology Reports

Volumn 2, Issue 2, 2000, Pages 123-131

  Jakubowiak, Andrzej ^a   Cammenga, Jorg ^a   Sokolic, Robert ^a   Alvarez, Sara ^a   Jackson, Geoffrey ^a   Hedvat, Cyrus ^a   Nimer, Stephen D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute Leukemia; Acute Myeloid Leukemia; Acute Promyelocytic Leukemia Cell; Arsenic Trioxide; Fusion Protein

Indexed keywords

FEMALE; GENETIC SCREENING; GENETICS; HUMAN; LEUKEMIA; MALE; METHODOLOGY; MOLECULAR BIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

FEMALE; GENETIC SCREENING; HUMANS; LEUKEMIA; MALE; MOLECULAR BIOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 0034156705     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0083-z     Document Type: Article

References (63)

1. Mannervik M, Nibu Y, Zhang H, Levine M: Transcriptional coregulators in development. Science 1999, 284:606–609. DOI: 10.1126/science.284.5414.606
2. Grignani F, De Matteis S, Nervi C, et al.: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815–818. This paper demonstrates that recruitment of histone deacetylase is critical for the transforming potential of APL fusion proteins; the differential effects of RA on the stability of the PML-RARa versus PLZF-RARa corepressor complex correlates with the retinoic acid-responsiveness of t(15;17) versus t(11;17) APLs. DOI: 10.1038/35901
3. Wong CW, Privalsky ML: Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem 1998, 273:27695–27702. DOI: 10.1074/jbc.273.42.27695
4. Gelmetti V, Zhang J, Fanelli M, et al.: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18:7185–7191.
5. Wang ZG, Ruggero D, Ronchetti S, et al.: PML is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266–272. DOI: 10.1038/3030
6. Lutterbach B, Westendorf JJ, Linggi B, et al.: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998, 18:7176–7184. The study demonstrates the interaction of ETO with the corepressors mSin3 and N-CoR and provides a model for how AML1/ETO can repress transcription of AML-1 targets.
7. Fenrick R, Amann JM, Lutterbach B, et al.: Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 1999, 19:6566–6574.
8. Lin RJ, Nagy L, Inoue S, et al.: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811–814. This study describes the importance of the PML-RARa and PLZF-RARa/histone deacetylase (HDAC) complex in the development of APL. Inhibitors of histone deacetylase dramatically potentiate retinoid-induced differentiation. DOI: 10.1038/35895
9. Hassig CA, Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997, 1:300–308. DOI: 10.1016/S1367-5931(97)80066-X
10. Cheng GX, Zhu XH, Men XQ, et al.: Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 1999, 96:6318–6323. The study shows the leukemogenic potential of the PLZF-RARa and NPM-RARa fusion genes in vivo using a transgenic mice model. DOI: 10.1073/pnas.96.11.6318
11. Pandolfi PP: Knocking in and out genes and trans genes: the use of the engineered mouse to study normal and aberrant hemopoiesis. Semin Hematol 1998, 35:136–148.
12. Soignet SL, Maslak P, Wang ZG, et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 998, 339:1341–1348.
13. Frank R, Zhang J, Uchida H, et al.: The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995, 11:2667–2674.
14. Meyers S, Lenny N, Hiebert SW: The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995, 15:1974–1982.
15. Lutterbach B, Hou Y, Durst KL, Hiebert SW: The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A 1999, 96:12822–12827. DOI: 10.1073/pnas.96.22.12822
16. Klampfer L, Zhang J, Zelenetz AO, et al.: The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 1996, 93:14059–14064. DOI: 10.1073/pnas.93.24.14059
17. Frank RC, Sun X, Berguido FJ, et al.: The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene 1999, 18:1701–1710. DOI: 10.1038/sj.onc.1202459
18. Levanon D, Goldstein RE, Bernstein Y, et al.: Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/ Groucho corepressors. Proc Natl Acad Sci U S A 1998, 95:11590–11595. DOI: 10.1073/pnas.95.20.11590
19. Imai Y, Kurokawa M, Tanaka K, et al.: TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem Biophys Res Commun 1998, 252:582–589. DOI: 10.1006/bbrc.1998.9705
20. Hiebert SW, Sun W, Davis JN, et al.: The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996, 16:1349–1355.
21. Uchida H, Downing JR, Miyazaki Y, et al.: Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene 1999, 18:1015–1022. DOI: 10.1038/sj.onc.1202383
22. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753–791. DOI: 10.1146/annurev.biochem.67.1.753
23. Kurokawa M, Mitani K, Imai Y, et al.: The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998, 92:4003–4012.
24. Kurokawa M, Mitani K, Irie K, et al.: The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998, 394:92–96. DOI: 10.1038/27945
25. Osato M, Asou N, Abdalla E, et al.: Biallelic and heterozygous point mutations in the runt domain of the AML1/ PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999, 93:1817–1824.
26. Song WJ, Sullivan MG, Legare RD, et al.: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166–175. This is the first example of the role of haploinsufficiency (due to genetic mutations within the AML1 gene) in a familial predisposition to developing leukemia. DOI: 10.1038/13793
27. Liu P, Tarle SA, Hajra A, et al.: Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993, 261:1041–1044. DOI: 10.1126/science.8351518
28. Goger M, Gupta V, Kim WY, et al.: Molecular insights into PEBP2/ CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta. Nat Struct Biol 1999, 6:620–623. DOI: 10.1038/10664
29. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB: Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 1998, 12:840–844. DOI: 10.1038/sj.leu.2401021
30. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998, 92:2322–2333.
31. Secker-Walker LM: General report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997. Leukemia 1998, 12:776–778. DOI: 10.1038/sj.leu.2401011
32. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, et al.: The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/ SNF complex. Proc Natl Acad Sci U S A 1998, 95:4152–4157. DOI: 10.1073/pnas.95.8.4152
33. Yu BD, Hanson RD, Hess JL, et al.: MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci U S A 1998, 95:10632–10636. DOI: 10.1073/pnas.95.18.10632
34. Dobson CL, Warren AJ, Pannell R, et al.: The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999, 18:3564–3574. DOI: 10.1093/emboj/18.13.3564
35. Shinobu N, Maeda T, Aso T, et al.: Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem 1999, 274:17003–17010. DOI: 10.1074/jbc.274.24.17003
36. Caligiuri MA, Strout MP, Lawrence D, et al.: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998, 58:55–59.
37. Schnittger S, Wormann B, Hiddemann W, Griesinger F: Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 1998, 92:1728–1734.
38. Blobel G: Unidirectional and bidirectional protein traffic across membranes. Cold Spring Harb Symp Quant Biol 1995, 60:1–10.
39. Pemberton LF, Blobel G, Rosenblum JS: Transport routes through the nuclear pore complex. Curr Opin Cell Biol 1998, 10:392–399. DOI: 10.1016/S0955-0674(98)80016-1
40. Borrow J, Shearman AM, Stanton VP Jr, et al.: The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996, 12:159–167. DOI: 10.1038/ng0296-159
41. Nakamura T, Largaespada DA, Lee MP, et al.: Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996, 12:154–158. DOI: 10.1038/ng0296-154
42. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, et al.: NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998, 58:4269–4273.
43. Arai Y, Hosoda F, Kobayashi H, et al.: The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood 1997, 89:3936–3944.
44. Kasper LH, Brindle PK, Schnabel CA, et al.: CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 1999, 19:764–776. The study demonstrates that the NUP98-HOXA9 fusion protein can dysregulate HOX-responsive genes through the ability of the nucleoporin-specific FG repeats to recruit the coactivator CBP/p300.
45. Nakamura T, Yamazaki Y, Hatano Y, Miura I: NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood 1999, 94:741–747.
46. Ahuja HG, Felix CA, Aplan PD: The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 1999, 94:3258–3261.
47. Hussey DJ, Nicola M, Moore S, et al.: The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 1999, 94:2072–2079.
48. Fornerod M, Boer J, van Baal S, et al.: Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995, 10:1739–1748.
49. von Lindern M, Fornerod M, Soekarman N, et al.: Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene. Baillieres Clin Haematol 1992, 5:857–879.
50. von Lindern M, van Baal S, Wiegant J, et al.: CAN, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol 1992,12:3346–3355.
51. Kraemer D, Wozniak RW, Blobel G, Radu A: The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm. Proc Natl Acad Sci U S A 1994, 91:1519–1523. DOI: 10.1073/pnas.91.4.1519
52. Salvati PD, Watt PM, Thomas WR, Kees UR: Molecular characterization of a complex chromosomal translocation breakpoint t(10;14) including the HOX11 oncogene locus. Leukemia 1999, 13:975–979. DOI: 10.1038/sj/leu/2401421
53. McWhirter JR, Neuteboom ST, Wancewicz EV, et al.: Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci U S A 1999, 96:11464–11469. DOI: 10.1073/pnas.96.20.11464
54. Asahara H, Dutta S, Kao HY, et al.: Pbx-Hox heterodimers recruit coactivator-corepressor complexes in an isoformspecific manner. Mol Cell Biol 1999,19:8219–8225.
55. Shen WF, Rozenfeld S, Kwong A, et al.: HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol 1999,19:3051–3061.
56. Chase A, Reiter A, Burci L, et al.: Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood 1999, 93:1025–1031.
57. Tenen DG, Hromas R, Licht JD, Zhang DE: Transcription factors, normal myeloid development, and leukemia. Blood 1997, 90:489–519.
58. Wang ND, Finegold MJ, Bradley A, et al.: Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995, 269:1108–1112. DOI: 10.1126/science.7652557
59. Zhang P, Iwama A, Datta MW, et al.: Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med 1998, 188:1173–1184. DOI: 10.1084/jem.188.6.1173
60. Wang X, Scott E, Sawyers CL, Friedman AD: C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999, 94:560–571.
61. Westendorf JJ, Yamamoto CM, Lenny N, et al.: The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998,18:322–333.
62. Pabst T, Mueller EU, Schnittger S, et al.: Dominant negative mutations of the tumor supressor CCAAT/Enhancer Binding Protein alpha (C/EBPalpha): Role in acute myeloid leukemia [abstract]. Blood 1999,94(suppl 1):624a.
63. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531–537. This report demonstrates the feasibility of classifying acute leukemia (myeloid vs lymphoid) based on the pattern of gene expression, using DNA microarray technology. DOI: 10.1126/science.286.5439.531